leisure time -WSS

leisure time

author：focus 2025-10-02 08:52:57 Page View：3985

Sanofi will license a new CRISPR enzyme from the startup Scribe Therapeutics in a bid to be the first to develop a safer, simpler, and more scalable cure for sickle cell disease.

The French drugmaker will pay Scribe $40 million upfront and promise another $1.2 billion in potential milestones to license a DNA-cutting enzyme called CasX for use in a potential single-infusion treatment for the serious blood disorder — what’s known as in vivo therapy.CasX was discovered in CRISPR pioneer Jennifer Doudna’s lab, which subsequently spun out Scribe.

Scribe was planning to announce the news Tuesday, but it was published early Monday by GEN.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： UnitedHealth quietly bought dozens of outpatient centers
Next article： Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

knowledge

Apple is now the first public company to be valued at $3 trillion

6:09FILE-AnApplelogoadornsthefacadeofthedowntownBrooklynApplestoreonMarch14,2020,inNewYork.Applebeca

RSV shot was 90% effective at preventing hospitalizations in kids

Thiselectronmicroscopeimageshowshumanrespiratorysyncytialvirus(RSV)virions,colorizedblue,andanti-RSV

The high cost of giving birth even with insurance

AdobeTheburdenofhighhealthcarecostsandmedicaldebtintheU.S.isnosecret.Medicaldebtaffectsoneinfiveadul

As H5N1 spreads in cows, experts warn against drinking raw milk

RobertF.Bukaty/APScientistswhoknowaboutthetypesofpathogens—E.coliandSalmonellaamongthem— thatcanbetr

leisure time

explore

knowledge

As H5N1 spreads in cows, experts warn against drinking raw milk